ASCO International Affairs Committee Leaders Discuss Global Oncology Priorities
As the global cancer burden grows, persistent inequities in cancer care underscore the need for locally tailored solutions and greater global exchange. The ASCO Post spoke with the ASCO International Affairs Committee’s current Chair, Piotr Rutkowski, MD, PhD, FASCO, of Poland; Immediate Past Chair Monica Malik, MD, DNB, FASCO, of India; and Chair-Elect Matías Chacón, MD, of Argentina, about these challenges and ASCO’s role in addressing them.
At the 2026 ASCO Annual Meeting, then-ASCO President Eric J. Small, MD, FASCO, made addressing these inequities central to his Presidential Address, calling on the oncology community to translate knowledge “across languages, cultures, geographies, resource availability, and practice sites, so that all patients can benefit.” (See the June 10, 2026, issue of The ASCO Post to read Dr. Small’s full President’s Address or visit ASCOPost.com.)
Different Dimensions of Inequity
“The biggest concern [in cancer care globally today] is equity…,” Dr. Malik said. As cancer incidence rises, she sees a widening gap in access to care, availability, and affordability—with the disparities particularly pronounced in low- and middle-income countries.
In India, she said, the greatest challenge is the sheer number of patients, which is straining an already stretched health-care system and thus compounding disparities. Those disparities should not, however, be understood simply as a lack of sophisticated oncology care; India has centers providing care comparable to leading centers globally, although access may depend on patients’ ability to reach and afford care in the urban areas where many are concentrated.
More broadly, she emphasized that inequity is not exclusive to lower-income countries; low-resource areas can exist within high-income countries as well.
Dr. Rutkowski shared Dr. Malik’s concern about growing cancer case numbers worldwide and expanded on the accompanying challenges, including diagnostic and treatment inequality—“one of the issues we have to stress….” Lower-income countries have less access to basic diagnostics and curative treatment, especially with newer expensive therapies. Although higher-income countries also face pressures from aging populations and rising treatment costs, he said disparities in cancer care are expected to contribute to a widening gap in mortality, citing projections of a 155% increase in cancer deaths in low-income countries compared with 56% in high-income countries by 2050.1
Importantly, he defined access as more than technical availability. Effective access also depends on having an organized health system—a particular challenge in Central and Eastern Europe, where he pointed to limited health care financing, gaps in prevention and screening uptake, delayed diagnoses, prolonged wait times for procedures, bureaucratic barriers to newer therapies, limited access to clinical trials, and overburdened workforces. These challenges are not uniform across the region, however, with access varying considerably among countries and between rural areas and major cities.
Building on Dr. Rutkowski’s discussion of rising cancer incidence and the health system barriers that can widen disparities, Dr. Chacón described inequity in outcomes as his greatest concern, identifying what he called a “deficit of implementation” as a contributor: the distance between what evidence indicates can be achieved and what health systems actually deliver. “There is not a difference in terms of knowledge,” he said. Rather, translating established knowledge into practice remains difficult, both globally and within his region.
In Argentina, there is a highly trained oncology workforce, along with modern diagnostic and treatment capabilities and access to clinical trials. Yet cancer care is delivered through three poorly coordinated subsystems: social security funds, private prepaid insurance, and the public sector, a fragmentation Dr. Chacón identified as the driver of inequity.
“We have the expertise, we have infrastructure, but there is no coherency or equity in trying to solve these problems,” he said. “Structural fragmentation of the health system is the main problem.”
Taken together, their perspectives suggest that inequity is not synonymous with an absence of oncology expertise. It may instead reflect where expertise is located, who can afford or reach it, whether health systems can effectively connect patients with available care, or whether evidence can be implemented across an entire health system.
Connecting Global Oncology Through ASCO
“When we think about ASCO, we think globally,” Dr. Rutkowski remarked. “In recent years, ASCO has developed several initiatives that will probably increase in the near future.”
When asked where ASCO can have its greatest international impact, the three leaders largely emphasized its ability to connect people and knowledge across countries while responding to locally identified needs.
Dr. Chacón identified three areas where ASCO could have particular international impact: adapting global evidence for lower-resource settings (ie, resource-stratified guidelines) developing the oncology workforce and new leaders (ie, the International Development and Education Award [IDEA]); and democratizing access to knowledge through digital and open-access tools.
Dr. Malik approached ASCO’s international role from the perspective of its global network: “What is unique about ASCO is how it brings together diverse people who work with oncology,” she said, citing medical, surgical, and radiation oncologists as well as pathologists, researchers, drug-development experts, and professionals working in quality, palliative care, and supportive care.
For oncologists in low- and middle-income countries, Dr. Malik highlighted IDEA as one way ASCO facilitates those connections. The program, she said, “has now helped hundreds of oncologists from [these countries] to come to this global platform to collaborate, network, develop leadership skills, and expand their mentorship opportunities and global outlook.”
“It has launched many careers and created leaders…,” she continued. Dr. Rutkowski similarly emphasized IDEA’s role in building lasting international networks, noting that the program pairs early-career oncologists from low- and middle-income countries with prominent ASCO mentors. Many current oncology leaders outside the United States are former IDEA grant fellows, he added, “which means it really impacts people’s lives and careers in oncology.”
Leadership development extends through other programs as well, Drs. Rutkowski and Malik suggested. Dr. Malik pointed to the Leadership Development Programand emphasized its reach into the Asia-Pacific and Latin American regions.
She identified research capacity as another important area of ASCO’s international work, singling out the International Innovation Grant, which funds pragmatic projects in low- and middle-income countries that “may not always be cutting-edge research or drug development” but can have substantial implications for cancer care in those settings. Dr. Rutkowski likewise identified expanding clinical trial equity in these countries as a long-term goal, citing clinical cancer research workshops held in his region as a way ASCO is supporting that effort.
But all three also emphasized that connecting oncology globally does not mean exporting the same approach everywhere. Dr. Malik described educational programs developed with local teams and partnerships with national oncology organizations as opportunities for “two-way” knowledge sharing. Dr. Rutkowski similarly emphasized this approach to education, while separately noting the role of resource-stratified guidelines as a way to adapt care pathways to regional infrastructure rather than Western-centric assumptions.
Regional councils (Asia-Pacific, Latin America, Sub-Saharan Africa, and Central and Eastern Europe) may provide one of the clearest mechanisms for putting that principle into practice, Dr. Rutkowski suggested. All three leaders emphasized the councils’ role in ensuring that ASCO’s international efforts reflect local priorities by bringing regional experts into identifying the issues that need to be addressed, with Dr. Chacón describing them as “one of the most important things that [the organization] provides to the world right now.”
For Dr. Rutkowski, however, the councils’ role could extend beyond addressing priorities within their respective regions: they could also facilitate knowledge exchange across regions. He pointed to the molecular tumor board program associated with the Central and Eastern Europe Council as one successful initiative that could be shared more broadly with other councils.
The leaders also highlighted other initiatives with international reach as well, including the Quality Oncology Practice Initiative Certification Program, global courses,and ASCO Breakthrough meetings. “More than 170 countries are attending ASCO meetings,” Dr. Rutkowski explained, “so, generally, it means that knowledge is dispersed everywhere.”
When Lessons Travel in Both Directions
Yet the connections fostered through ASCO’s international programs are not simply about bringing knowledge and resources to lower-resource settings, the three leaders emphasized. They also create opportunities for approaches developed in these settings to inform cancer care elsewhere, including in wealthier health systems.
Research from India on low-dose immunotherapy and hypofractionation illustrates that potential, according to Dr. Malik. By reducing costs and improving access where resources are limited, she said, the same strategies may help address rising cancer care costs in high-income countries.
“If we prove that less is enough or not inferior,” whether through a lower drug dose or fewer radiation fractions, the findings could improve sustainability internationally, she explained. “Countries like India and other low- and middle-income countries can and are taking the lead in driving these kinds of innovative practices.”
Dr. Rutkowski described digitalization as a strength in parts of Central and Eastern Europe. In Estonia, he said, “almost everything is digitalized,” while in Latvia he encountered a centralized system that allowed him to access a patient’s examinations using a code, with imaging from across the country unified in one place. He said digitalization in the region also enabled electronic prescriptions and arrangements for examinations, capabilities that proved useful during the COVID-19 pandemic and remain in use today.
Another example came from Argentina, where Dr. Chacón discussed a cervical cancer screening program in which community health workers offered HPV DNA self-collection during routine home visits. He said the approach could be adapted for other parts of the world where cervical cancer remains a substantial cause of mortality.
Developing the Next Generation
For Drs. Malik, Rutkowski, and Chacón, carrying that international exchange of ideas and innovations forward will require ASCO to continue creating opportunities for the next generation of oncologists.
Dr. Malik emphasized mentorship that can reach early-career oncologists regardless of geography or resources, pointing to virtual mentoring and other ASCO global initiatives. Mentorship was also a priority for Drs. Chacón and Rutkowski, with Dr. Chacón emphasizing its importance for those in low- and middle-income countries who may work in relative professional isolation.
He called for “sustained and accessible resource-appropriate education,” including digital education to overcome barriers related to cost and distance, with Spanish-language resources to expand its accessibility in Latin America.
Dr. Malik also highlighted collaborative multinational research to give early-career investigators opportunities to build research capacity. That priority was shared by Dr. Rutkowski: “Our region is very willing to build all these academic trials,” he said, but funding alone is not enough; oncologists need the training to conduct those trials properly.
Dr. Chacón echoed that need for research training, stating that institutions in low- and middle-income countries should not serve “just as recruitment sites for clinical trials.” Instead, early-career investigators need “genuine training in clinical trial design and implementation science” that allows them to pursue locally relevant research questions. He identified developing leaders and retaining the next generation of oncologists in their home countries as priorities as well.
Similarly citing leadership development as a priority, Dr. Rutkowski described ASCO’s programs for this purpose as a form of structured education that can help early-career oncologists build cross-border peer networks and foster regional collaboration to tackle systemic hurdles locally. He saw a role for multidisciplinary education in addressing regional gaps in cancer care standards as well, again highlighting the molecular tumor board program as one approach.
‘We Can Do More Together’
As the three leaders considered what comes next for global oncology, their perspectives were shaped by their experiences working across regions. Dr. Malik said she has learned equally from oncologists in high- and low-income countries. “The most important thing is collaboration,” she said, describing efforts to improve equity and sustainability as “a team job” requiring people from different parts of the world to work toward a shared vision.
“We can grow if we come together,” she added, “and ASCO is very well positioned to facilitate this, being the global organization that it is.”
Dr. Chacón said collaborating internationally had changed his perspective “profoundly.” He had thought about global oncology largely in terms of disparities—differences in resources and outcomes across a map—but discussions with colleagues from other regions made him see that “the problem is global.”
“Every patient, wherever they live, has a chance,” Dr. Chacón said. Oncologists, he added, “have a great deal to learn from each other. This is bidirectional.”
As Chair-Elect, Dr. Chacón said one of his priorities will be narrowing gaps in cancer care through implementation. The challenge is no longer simply generating more knowledge, he said, but translating what oncologists already know into practice. He also wants the regional councils to mature into “genuine engines” for international work.
However, his longer-term vision is for global oncology to reach a point where geography no longer creates such divisions in cancer care. “I want to see a society of the world where we can just discuss cancer,” he said, rather than having to consider the “international aspects” of oncology separately. For Dr. Rutkowski, narrowing global cancer care gaps will require ensuring that ASCO’s existing international programs become better known and more widely used around the world. He wants to see greater sharing of knowledge, stronger local clinical trial networks with more oncologists trained in clinical research, and improved survival rates in low- and middle-income regions.
Dr. Rutkowski would also like to see greater attention given to survivorship as cancer survival improves, including broader use of ASCO’s Cancer Treatment & Survivorship Care Plans. He described the growing challenge as “how to live after cancer”—particularly in lower-income countries where survivorship has historically received less attention.
Dr. Rutkowski’s broader message was simple: “Cancer has no borders.” Despite ASCO’s international programs already in place, he added, “I still think that we can do more together.”
DISCLOSURE: Dr. Rutkowski has received honoraria from and served on advisory boards for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Merck, Philogen, Immunome, Cogent, GENESIS Pharma, and Medison Pharma; has served as a member of an independent data monitoring committee for Erasca; and has received research funding from Pfizer and Bristol Myers Squibb. Dr. Malik reported no conflicts of interest. Dr. Chacón has received honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, and Pfizer. Dr. Small reported no conflicts of interest.
REFERENCE
1. Balch CM, Liao N, Lam DSC, et al: The global cancer crisis: A review of growing burden, deepening inequality and initiatives for prevention and early detection. Ecancermedicalscience 20:2071, 2026.